ADAM17 Mediates MMP9 Expression in Lung Epithelial Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Li, Ya Qing ^a   Yan, Jian Ping ^a   Xu, Wu Lin ^a   Wang, Hong ^a   Xia, Ying Jie ^a   Wang, Hui Jun ^a   Zhu, Yue Yan ^a   Huang, Xiao Jun ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; GELATINASE B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PYRROLIDINE DITHIOCARBAMATE; RECOMBINANT TUMOR NECROSIS FACTOR; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1 BLOCKING PEPTIDE; UNCLASSIFIED DRUG; VIRUS RNA;

ADAM17 GENE; ARTICLE; CYTOKINE PRODUCTION; CYTOPLASM; DOSE RESPONSE; ENZYME INHIBITION; EPITHELIUM CELL; GENE; GENE TARGETING; GENETIC REGULATION; HUMAN; HUMAN CELL; LENTIVIRINAE; LUNG ALVEOLUS EPITHELIUM; MODULATION; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; RNA SEQUENCE; SIGNAL TRANSDUCTION;

ADAM PROTEINS; CELL LINE; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; I-KAPPA B PROTEINS; LENTIVIRUS; LIPOPOLYSACCHARIDES; LUNG; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PHOSPHORYLATION; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

LENTIVIRUS;

EID: 84872294171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051701     Document Type: Article

References (34)

1. Van Gestel AJR, Steier J, (2010) Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD). J Thorac Dis 2: 215-222.
2. Bellayr IH, Mu X, Li Y, (2009) Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments. Future Med Chem 1: 1095-1111.
3. Davey A, McAuley DF, O'Kane CM, (2011) Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J 38: 959-970.
4. Klein T, Bischoff R, (2011) Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41: 271-290.
5. Yan C, Boyd DD, (2007) Regulation of matrix metalloproteinase gene expression. Cell Physiol 211: 19-26.
6. Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, et al. (2008) Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 294: L1149-L1157.
7. Ramos C, Cisneros J, Gonzalez-Avila G, Becerril C, Ruiz V, et al. (2009) Increase of matrix metalloproteinases in woodsmoke-induced lung emphysema in guinea pigs. Inhal Toxicol 21: 119-132.
8. Legrand C, Gilles C, Zahm JM, Polette M, Buisson AC, et al. (1999) Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol 146: 517-529.
9. Maclay JD, McAllister DA, Rabinovich R, Haq I, Maxwell S, et al. (2012) Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 67: 606-612.
10. Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF, (2004) Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 126: 1802-1810.
11. Vlahos R, Wark PA, Anderson GP, Bozinovski S, (2012) Glucocorticosteroids differentially regulate MMP-9 and neutrophil elastase in COPD. PLoS One 7: e33277.
12. Brajer B, Batura-Gabryel H, Nowicka A, Kuznar-Kaminska B, Szczepanik A, (2008) Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol 59: 145-152.
13. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, et al. (2009) Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 103: 1231-1238.
14. Mukhopadhyay S, Hoidal JR, Mukherjee TK, (2006) Role of TNFalpha in pulmonary pathophysiology. Respir Res 7: 125.
15. Baud V, Derudder E, (2011) Control of NF-κB activity by proteolysis. Curr Top Microbiol Immunol 349: 97-114.
16. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733.
17. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, et al. (2002) The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 41: 9462-9469.
18. Lee SO, Jeong YJ, Yu MH, Lee JW, Hwangbo MH, et al. (2006) Wogonin suppresses TNF-alpha-induced MMP-9 expression by blocking the NF-kappaB activation via MAPK signaling pathways in human aortic smooth muscle cells. Biochem Biophys Res Commun 351: 118-125.
19. Balasubramanian S, Fan M, Messmer-Blust AF, Yang CH, Trendel JA, et al. (2011) The interferon-gamma-induced GTPase, mGBP-2, inhibits tumor necrosis factor alpha (TNF-alpha) induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-kappaB and Rac protein. J Biol Chem 286: 20054-20064.
20. Takizawa T, Gemma A, Ui-Tei K, Aizawa Y, Sadovsky Y, et al. (2010) Basic and clinical studies on functional RNA molecules for advanced medical technologies. J Nippon Med Sch 77: 71-79.
21. Schambach A, Baum C, (2008) Clinical application of lentiviral vectors- concepts and practice. Current Gene Therapy 8: 474-482.
22. Wright C, Pilkington R, Callaghan M, McClean S, (2011) Activation of MMP-9 by human lung epithelial cells in response to the cystic fibrosis-associated pathogen Burkholderia cenocepacia reduced wound healing in vitro. Am J Physiol Lung Cell Mol Physiol 301: L575-L586.
23. Deshmukh HS, Shaver C, Case LM, Dietsch M, Wesselkamper SC, et al. (2008) Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production. Am J Respir Cell Mol Biol 38: 446-454.
24. Martin TR, (2000) Recognition of bacterial endotoxin in the lungs. Am J Respir Cell Mol Biol 23: 128-132.
25. Kanarek N, Ben-Neriah Y, (2012) Regulation of NF-κB by ubiquitination and degradation of the IκBs. Immunol Rev 246: 77-94.
26. Huxford T, Huang DB, Malek S, Ghosh G, (1998) The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 95: 759-770.
27. Johnson C, Van Antwerp D, Hope TJ, (1999) An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IkappaBalpha. EMBO J 18: 6682-6693.
28. Li YQ, Zhang ZX, Xu YJ, Ni W, Chen SX, et al. (2006) N-Acetyl-L-cysteine and pyrrolidine dithiocarbamate inhibited nuclear factor-kappaB activation in alveolar macrophages by different mechanisms. Acta Pharmacol Sin 27: 339-346.
29. Kollias G, Kontoyiannis D, (2002) Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13: 315-321.
30. Edwards DR, Handsley MM, Pennington CJ, (2008) The ADAM metalloproteinases. Mol Aspects Med 29: 258-289.
31. Monika G, (2010) ADAM-17: The Enzyme That Does It All. Crit Rev Biochem Mol Biol 45: 146-169.
32. Scheller J, Chalaris A, Garbers C, Rose-John S, (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32: 380-387.
33. Zheng Y, Saftig P, Hartmann D, Blobel C, (2004) Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 279: 42898-42906.
34. Singer O, Verma IM, (2008) Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr Gene Ther 8: 483-488.